| Clinical Evaluation | 
|---|
| Glucose metabolism | 
| Type of Imaging | 
| PET | 
| Grade of Recommendation | 
| C/D (optional) | 
| Level of Evidence | 
| well-established clinical and Nuclear Medicine recommendations | 
| Effective Dose | 
| 19.0 µSv/MBq | 
| Bibliographic Reference | 
| 
                         
                            
                                Taïeb, D., Hicks, R.J., Hindié, E., Guillet, B.A., Avram, A., Ghedini, P., Timmers, H.J., Scott, A.T., Elojeimy, S., Rubello, D., Virgolini, I.J., Fan...
                            
                            
                                read more
                            
                         
                        
                            
                                Taïeb, D., Hicks, R.J., Hindié, E., Guillet, B.A., Avram, A., Ghedini, P., Timmers, H.J., Scott, A.T., Elojeimy, S., Rubello, D., Virgolini, I.J., Fanti, S., Balogova, S., Pandit-Taskar, N., Pacak, K. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019; https://doi.org/10.1007/s00259-019-04398-1
                            
                            
                                read less
                            
                         
                     | 
                
| Guide to Nuclear Medicine | 
| Read the corresponding chapter |